HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/1/2017)... , ... March 01, 2017 , ... ... healing grace in the lives of those who hear His voice. “Cleansing Thoughts; ... a retired Christian bookstore proprietor who enjoys boating, gardening and crocheting baby items ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... “Our Pure Need of Obedience to the ... preparation for His return. “Our Pure Need of Obedience to the Law of God” is ... to attend missionary school. He and his wife, Anika, and children have since dedicated their ...
(Date:2/28/2017)... ... ... e-Zest Solutions ( http://www.e-zest.com ) – Digital Transformation leader ... intelligent mobile platform that is enabling sales people at small businesses to Fortune ... users in mind unlike most enterprise software, to improve their productivity by making ...
(Date:2/28/2017)... ... February 28, 2017 , ... Many of the country’s top ... Solutions to Healthcare’s Greatest Challenges,” during Intalere’s 2017 Executive Forum, taking place March ... Forum assembles the best and brightest healthcare leaders to exchange experiences, expertise and ...
(Date:2/28/2017)... Baltimore, MD (PRWEB) , ... February 28, 2017 , ... ... Healthcare are co-hosting a Wellness Day on March 4, 2017 from 10:00 a.m. to ... San Mateo and Menaul Blvds. , The goal of the Wellness Day is to ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... , March 1, 2017 The global  Intraoperative Neuromonitoring ... a new report by Grand View Research, Inc. The intraoperative neuromonitoring market is ... to the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. ... ... Grand View Research Logo ...
(Date:2/28/2017)... -- Prefilled Syringes Market: Scope and Segmentation Download ... report provides a forecast and analysis of the ... levels. It provides historical data of 2015 along ... of revenue (US$ Mn) and volume (Bn Units). ... an outlook on prefilled syringes consumption globally. It ...
(Date:2/28/2017)... , Feb. 28, 2017 Persistence Market ... global dysphagia management market in a new publication ... Forecast 2016-2024." As the name suggests, we have ... geographical regions and on the basis of the ... assessment of the opportunities available to all the ...
Breaking Medicine Technology:
Cached News: